Shopping Cart
- Remove All
Your shopping cart is currently empty
Argentina
Australia
Austria
Belgium
Brazil
Bulgaria
Croatia
Cyprus
Czech
Denmark
Egypt
Estonia
Finland
France
Germany
Greece
Hong Kong
Hungary
Iceland
India
Ireland
Israel
Italy
Korea
Latvia
Lebanon
Malaysia
Malta
Morocco
Netherlands
New Zealand
Norway
Poland
Portugal
Romania
Singapore
Slovakia
Slovenia
Spain
Sweden
Switzerland
Taiwan,China
Thailand
Turkey
United Kingdom
United States
Other Countries
Select your Country or Region
Enzaplatovir
Contact us for more batch information
Enzaplatovir
Catalog No. T27271Cas No. 1323077-89-9
Enzaplatovir (BTA-585) is an orally available fusion inhibitor with antiviral activity for the study of respiratory syncytial virus infections and coronavirus disease (COVID-19) infections.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose. | Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $215 | In Stock | |
| 5 mg | $538 | In Stock | |
| 10 mg | $868 | In Stock | |
| 25 mg | $1,520 | In Stock | |
| 50 mg | $1,980 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $589 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Enzaplatovir"
Rilematovir
T156211383450-81-4
Rilematovir (JNJ-678) is an inhibitor of fusion protein with antiviral activity and low cytotoxicity. Rilematovir can be used in studies about respiratory syncytial virus treatment.
- $40
Size
QTY
Presatovir
TQ00851353625-73-6
Presatovir (GS-5806) (GS-5806) is a novel, orally bioavailable RSV fusion inhibitor (mean EC50: 0.43 nM).
- $97
Size
QTY
Rostafuroxin
Cited
T2621156722-18-8
Rostafuroxin (PST 2238) has been used in trials studying the treatment of Essential Hypertension.
- $37
Size
QTY
CitedPalivizumab
T76907188039-54-5
Palivizumab (MEDI 493) is a humanized RSV-specific monoclonal antibody that selectively inhibits epitopes at the F protein A antigenic site of RSV subtypes A and B for the prevention of respiratory syncytial virus infection (RSV).
- $228
Size
QTY
Suptavumab
T769921629615-23-1
Suptavumab (REGN2222) is a human monoclonal antibody. Suptavumab neutralizes conserved epitopes on subtypes A and B on RSV. Suptavumab can be used to study RSV infections and the respiratory system.
- $328
Size
QTY
VV116
T600162647442-33-7
VV116 (JT001) is a selective and orally active nucleoside antiviral agent against respiratory syncytial virus (RSV) and SARS-CoV-2 infection.
- $93
Size
QTY
Ac-CoA Synthase Inhibitor1
T4380508186-14-9
Ac-CoA Synthase Inhibitor1 (ACSS2 inhibitor) is the most potent and specific inhibitor of acetate-dependent acetyl-CoA synthetase 2 (ACSS2).
- $41
Size
QTY
Ribavirin Cited
T068436791-04-5
Ribavirin (Tribavirin) is a synthetic nucleoside analog of ribofuranose with activity against hepatitis C virus and other RNA viruses.
- $39
Size
QTY
CitedGS-443902
T55391355149-45-9
GS-441524 was shown to be a safe and effective treatment for feline infectious peritonitis (FIP). The optimum dosage was found to be 4.0 mg/kg SC q24h for at least 12 weeks
- Inquiry Price
Size
QTY
Sisunatovir hydrochloride
T91971903763-83-6
Sisunatovir hydrochloride (RV521 HCl) is an orally available inhibitor of the RSV-F protein that has exhibited potent efficacy against a panel of clinical isolates of RSV-A and RSV-B viruses in vitro (IC50 = 1.4 nM for RSV-A, IC50 = 1.0 nM for RSV-B).
- $55
Size
QTY
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Enzaplatovir (BTA-585) is an orally available fusion inhibitor with antiviral activity for the study of respiratory syncytial virus infections and coronavirus disease (COVID-19) infections. |
| Alias | BTAC585, BTA 585, BTA585, BTA-C585, BTA-585 |
| Molecular Weight | 377.4 |
| Formula | C20H19N5O3 |
| Cas No. | 1323077-89-9 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 150 mg/mL (397.46 mM) | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。 Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Dose Conversion
You can also refer to dose conversion for different animals. More
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.